ライブ

FierceBiotechIcon opens early-phase research unit in San Antonio, plus satellite clinics to grow trial capabilities Endpoints NewsValneva to cut up to 15% of jobs as reduced travel hits vaccine demand WatersWaters Corporation stock (US9418481035): Analytical instruments leader for US life sciences - AD HOC NEWS BioPharma DiveFDA’s leadership void leaves biotech with renewed ‘uncertainty’Endpoints NewsAbeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3 BioPharma DiveLilly data point to ‘maintenance’ strategies for GLP-1 weight loss FierceBiotechHumacyte cuts spending, staff as it seeks to boost sluggish sales for its off-the-shelf artery implant FierceBiotechWith $1B Novo deal and diabetes ambitions undimmed, Lexicon is in ‘good shape to go crazy’BioWorldNvision secures $55 million, with backing from Abbott BioWorldAppointments and advancements for May 13, 2026 BioWorldFinancings for May 13, 2026 BioWorldIn the clinic for May 13, 2026

BioWorld 2026年5月13日

Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal

In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early d...

In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early development programs in the fields of oncology, hematology and immunology. Shanghai-based Hengrui will hold exclusive rights in mainland China, Hong Kong and Macau, while Princeton, N.J.-based BMS will hold exclusive rights in the rest of the world.